MedTrace Logo

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

NCT03505554 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-08-07

No results posted yet for this study

Summary

The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.

Conditions

  • Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions

DRUG

Lorlatinib

100 mg QD

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • CARLO GAMBACORTI-PASSERINI, MD · University of Milano Bicocca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-10
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03505554 on ClinicalTrials.gov